Novartis To Pay $125 Million To Acquire Chinese Vaccine Maker
This article was originally published in PharmAsia News
Executive Summary
SHANGHAI - After disclosing this week that the company intends to channel a remarkable $1 billion into expanding an R&D center in Shanghai, Novartis revealed that it will pay $125 million to acquire an 85 percent stake in Zhejiang Tianyuan, the second-largest H1N1 vaccine provider in China
You may also be interested in...
China’s Best Shot: GSK, Novartis Gear Up For Vaccine Prime Time
With its large population, one-child policy and increasing emphasis on preventative care, China is poised for a vaccine boom. The catalyst for growth may come from the expected modernization of the country’s massive national immunization program.
Merck Expands Deal With Chinese Vaccines Firm As MNCs Look To Recover From China Pharmacopeia Issue
Merck is including its vaccine distribution partner Chongqing Zhifei in its development plan for at least two vaccines in China, while global firms regain a footing after new standards in the Chinese Pharmacopeia stilted their market growth.
Merck Expands Deal With Chinese Vaccines Firm As MNCs Look To Recover From China Pharmacopeia Issue
Merck is including its vaccine distribution partner Chongqing Zhifei in its development plan for at least two vaccines in China, while global firms regain a footing after new standards in the Chinese Pharmacopeia stilted their market growth.